Benign prostatic hyperplasia (BPH) is the most common urological disease in men, affecting about 33% of men in their 60 years (De Nunzio et al., 2011). With regard to prostate cancer, it is the second leading cause of cancer deaths in men after lung cancer (Siegel, Miller, & Jemal, 2018). BPH and prostate cancer are formed in different areas of the prostate and coexist in the same area only in 20% of cases (De Nunzio et al., 2011). They are considered as chronic diseases with early initiation and slow progression, and several risk factors are associated with them including obesity, poor diet, tobacco, radiation, environmental pollutants, lack of physical activity and ageing (Patel, 2016). The conventional therapy for BPH involves two main drug classes: alpha blockers and 5α-reductase inhibitors (Füllhase & Schneider, 2016), while chemotherapy and hormone therapy are utilised to fight against prostate cancer (Adsul et al., 2015). Unfortunately, these drugs are still limited because of their side effects, tumour resistance and high cost